Is Ustekinumab a targeted drug?

Ustekinumab (Ustekinumab) is a targeted drug. It is a type of biologic agent used to treat certain autoimmune diseases, such as Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Ustekinumab acts on specific cytokines and inhibits their effects on the immune system, thereby reducing the inflammatory response. This drug treats disease by targeting specific molecules and pathways to enhance treatment effectiveness and reduce side effects.

Ustekinumab downregulates the gene expression of inflammatory cytokines and chemokines (such asMCP-1, TNF-α, IP-10 and IL-8). Elevated levels of certain cytokines during chronic inflammation may alter the formation of cytochrome P-450 enzymes. Studies have shown an inverse relationship between plasma levels of inflammatory cytokines and the formation and activity of CYP450 enzymes. Although ustekinumab may normalize CYP enzyme formation and enhance CYP-mediated drug metabolism, it has no clinically significant effect on human CYP enzyme activity. Steady state was reached after 28 weeks of repeated subcutaneous administration in adult patients with psoriasis.

The generic drug Ustekinumab has been launched in China and is included in the medical insurance, and is only reimbursed for patients who meet the indications. The price of the 130mg/26ml intravenous injection preparation may be more than 5,000 yuan per box, and the price of the 90mg: 1.0ml*1 subcutaneous injection preparation may be more than 8,000 yuan per box. The price of the 130mg/26ml intravenous injection preparation of Ustekinumab sold overseas may be more than 2,000 US dollars per box, and the price of 45mg: 0.5ml*1 subcutaneous injection preparation per box may be more than 10,000 US dollars. There are currently no generic versions of ustekinumab produced in other overseas countries.